ArticleCureus2024
Evaluation of the Cerebrospinal Fluid (CSF)-Truenat Assay: A Novel Chip-Based Test in the Diagnosis and Management of Tubercular Meningitis at a Tertiary Care Hospital.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diagnosis of Tuberculous Meningitis: Integrating Clinical Assessment and Molecular Diagnostics.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTuberculosis (TB) continues to be a major health concern that has a significant impact on morbidity and mortality worldwide. Tubercular meningitis (TBM) may be fatal due to its severe neurological outcomes if not diagnosed and treated promptly. The newer molecular diagnostic techniques have brought significant advancements in the detection of
methodsA cross-sectional study was conducted on 150 patients. The CSF samples were analyzed by both cartridge-based nucleic acid amplification test (CBNAAT) and Truenat (Molbio Diagnostics Private Limited, Verna, Goa, India). Brain imaging was also performed. Patients were divided into four groups, i.e., definite, probable, possible, and non-TBM. Truenat-positive cases were considered definite, and their efficacy and clinical utility for diagnosing and managing TBM were compared with CBNAAT.
resultsA comparative analysis between CBNAAT and Truenat showed concordance for positive results. But it also identified some discrepancies, particularly in cases where CBNAAT was positive and Truenat was negative. Overall, Truenat demonstrated strong diagnostic performance with a sensitivity of 83.75%, a specificity of 88.57%, and overall accuracy of 86% as compared to CBNAAT.
conclusionThe study highlighted the role of Truenat in improving diagnostic accuracy and guiding cost-effective treatment strategies for TBM as compared to CBNAAT. As molecular tests alone cannot detect bacilli in most cases, a combination of clinical, microbiological, and radiological parameters is also obligatory for diagnosing TBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.